- Conditions
- Chronic Graft Versus Host Disease
- Interventions
- Belumosudil, Placebo, Prednisone, Prednisolone
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 24
- States / cities
- Little Rock, Arkansas • Duarte, California • San Francisco, California + 21 more
Location Directory
Clinical trials in Indianapolis, Indiana
This page shows live ClinicalTrials.gov search results for Indianapolis, Indiana, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
8617
Shown on this page
12
Current sort
Recently updated
Location scope
Indianapolis, IN
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 661–672 of 8,617 matching trials in Indianapolis, IN.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Healthy Subjects
- Interventions
- Transcutaneous Auricular Vagus Nerve Stimulation
- Device
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Peripheral Vascular Diseases
- Interventions
- Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device.
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 53
- States / cities
- Jonesboro, Arkansas • Los Angeles, California • Sacramento, California + 42 more
- Conditions
- Atopic Dermatitis
- Interventions
- Upadacitinib 15mg Dose, Dupilumab 300mg Dose, Upadacitinib 30mg Dose
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 63 Years
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 84
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 70 more
- Conditions
- Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer
- Interventions
- Torvutatug samrotecan, Bevacizumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 26
- States / cities
- Anchorage, Alaska • Miami, Florida • Indianapolis, Indiana + 21 more
- Conditions
- Germ Cell Tumor, Seminoma, Non-seminomatous Germ Cell Tumor, Ovarian Germ Cell Tumor
- Interventions
- Cabozantinib
- Drug
- Lead sponsor
- Jennifer King
- Other
- Eligibility
- Not listed
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Breast Cancer
- Interventions
- HCQ, Avelumab, Palbociclib
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 7
- States / cities
- Washington D.C., District of Columbia • Chicago, Illinois • Indianapolis, Indiana + 4 more
- Conditions
- Delayed Onset Muscle Soreness
- Interventions
- Kinesiotape
- Device
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Sickle Cell Disease
- Interventions
- Rilzabrutinib, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 10 Years to 65 Years
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Clovis, California + 17 more
- Conditions
- Gram-negative Bacterial Infection
- Interventions
- Part A: ATM-AVI Single Dose, Cohorts 1-4, Part B: Multiple-dose ATM-AVI, Cohorts 1-4
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- Up to 39 Weeks
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 11
- States / cities
- Orange, California • Aurora, Colorado • Indianapolis, Indiana + 4 more
- Conditions
- Traumatic Brain Injury
- Interventions
- C-Mill VR+ by Motek, Walk-over-Ground
- Device
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Stroke
- Interventions
- Walk-over-Ground, C-Mill VR+ by Motek
- Device
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana